首页> 外文期刊>Journal of Gynecologic Oncology >Treatment outcomes of high-dose-rate intracavitary brachytherapy for cervical cancer: a comparison of Ir-192 versus Co-60 sources
【24h】

Treatment outcomes of high-dose-rate intracavitary brachytherapy for cervical cancer: a comparison of Ir-192 versus Co-60 sources

机译:高剂量率腔内近距离放射治疗宫颈癌的治疗结果:Ir-192与Co-60来源的比较

获取原文
           

摘要

Objective To determine and compare treatment outcomes between cobalt-60 (Co-60) and iridium-192 (Ir-192) high dose rate (HDR) brachytherapy in stage IB2–IIIB cervical cancer patients at Department of Radiology, Faculty of Medicine Vajira Hospital, Navamindrahiraj University. Methods A retrospective cohort study of patients diagnosed with cervical cancer and treated with radiotherapy at the Department of Radiation Oncology, Faculty of Medicine Vajira Hospital between 2004 and 2014. Survival rate was analyzed by Kaplan-Meier method and were compared between groups with log-rank test. Multivariate analysis was performed using Cox proportional hazards model. Results A total of 480 patients with cervical cancer and treated with radiotherapy were included, 274 patients for Ir-192 group and 206 patients for Co-60 group. The 2- and 5-year disease-free survival rate in Ir-192 group were 80.4% and 73.1% and in Co-60 group were 82.5% and 74.7%, respectively (p=0.365). Overall survival rates at 2 and 5 years were 89.4% and 77% of the Ir-192 group, and 91.6% and 81.9% in the Co-60 group, respectively (p=0.238). The complications were primarily grade 1 or 2. Grade 3 and 4 complications were found in 13 of 274 and 7 of 206 in Ir-192 and Co-60 groups, respectively (p=0.232). Grade and clinical stage of cancer significantly affected the survival outcome. Conclusion Cervical cancer patients who were treated with HDR Co-60 brachytherapy were comparable in survival and toxicity outcomes of those with HDR Ir-192 brachytherapy. Co-60 source has lots of economic advantages over Ir-192 and hence suitable for low resource radiotherapy setting.
机译:目的确定和比较在Coajira医院放射科的IB2-IIIB期宫颈癌患者中,钴60(Co-60)和铱192(Ir-192)高剂量率(HDR)近距离放射疗法的治疗结果,Navamindrahiraj大学。方法回顾性队列研究2004年至2014年间在瓦吉拉医院放射肿瘤科诊断为宫颈癌并接受放射治疗的患者。采用Kaplan-Meier方法分析存活率,并与对数等级进行比较测试。使用Cox比例风险模型进行多变量分析。结果共纳入480例接受放射治疗的宫颈癌患者,Ir-192组274例,Co-60组206例。 Ir-192组的2年和5年无病生存率分别为80.4%和73.1%,而Co-60组的2年和5年无病生存率分别为82.5%和74.7%(p = 0.365)。 Ir-192组2年和5年总生存率分别为89.4%和77%,Co-60组分别为91.6%和81.9%(p = 0.238)。并发症主要为1级或2级。在Ir-192和Co-60组中,分别在274例中的13例和206例中的7例中发现3级和4级并发症(p = 0.232)。癌症的等级和临床阶段显着影响生存结果。结论接受HDR Co-60近距离放射治疗的宫颈癌患者在生存和毒性方面与接受HDR Ir-192近距离放射治疗的患者相当。 Co-60放射源比Ir-192具有很多经济优势,因此适用于低资源放射治疗环境。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号